Category Archives: MS Treatment

ALISO VIEJO, Calif., June 1, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (AVNR) today announced the presentation of three posters, including preliminary results from the PRISM patient registry, at the Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis. PRISM Registry The aims of the PRISM registry are to define pseudobulbar affect (PBA) prevalence and its quality of life (QoL) impacton patients with the associated underlying neurologic conditions of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, and traumatic brain injury (TBI). Results At the time of the data-cut a total of 3,647 patients with the six underlying neurologic conditions had enrolled in the PRISM registry. Among the enrolled patients, a total of 37.3% of all participants (n=1,361) had a positive screening score for PBA as measured by a CNS-LS13. The range of positive screening for PBA was similar across all the disease states (range of 34.7% to 40.0%); the prevalence of positive screens was also similar in the MS patient group (38.7%; n=354). The table below displays interim positive PBA screening rates of the current registry participants by underlying neurologic diagnosis. These prevalence … Continue reading →

WALTHAM, Mass.--(BUSINESS WIRE)-- N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today the appointment of Christine Cournoyer as the companys Chief Executive Officer. Ms. Cournoyer brings to N-of-One more than 25 years of executive leadership experience with healthcare technology companies, including her position as President and Chief Operating Officer of Picis, a provider of health information software solutions installed in more than 1,800 medical centers and hospital systems worldwide prior to its acquisition by United Healthcare in 2010. Jennifer Levin Carter, MD, MPH, the companys founder and President, will remain President and has taken on additional responsibility as Chief Medical Officer, an expanded role to lead further product development of N-of-Ones diagnostic and treatment strategy roadmaps for wider use by healthcare providers and other collaborators. Over the past four years, weve helped hundreds of cancer patients access our diagnostic and treatment strategy roadmaps as we developed and systematized our PrecisionWorks platform, said Dr. Carter. N-of-One is now positioned to scale this platform to power oncologists, regional cancer centers, and provider networks anywhere with leading-edge, data-driven knowledge and decision-support tools. We are extremely pleased that Chris, a distinguished and proven leader in the … Continue reading →

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present research at the 4th Collaborative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) that examines the impact of walking impairment on different aspects of the lives of people with multiple sclerosis (MS), as well as the use of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg in the United States. The six company-sponsored posters will be presented on Friday, June 1 at the CMSC/ACTRIMS meeting, being held in San Diego, CA. AMPYRA is the only FDA-approved therapy to improve walking in people with MS. Although walking is one of our most critical functional capabilities, and is impaired in more than half of all MS patients, there has been limited research on the pharmacologic treatment of walking impairment in MS. In part this was due to the lack of treatment options prior to AMPYRAs availability in 2010, said Ron Cohen, M.D., Acorda Therapeutics President and CEO. By supporting research that explores ways to better characterize walking impairment and more precisely quantify its impact in real-world settings, we can gain a better understanding of how improved walking may benefit people with … Continue reading →

29-05-2012 03:06 Extraordinary world first research carried out in Australia could transform the treatment and lives of people with MS See more at Visit link: MS breakthrough - Video … Continue reading →

Internationally acclaimed photographer creates first-of-its-kind exhibit highlighting the struggles, hopes and personal choices upon diagnoses A new photo exhibit created by Caitlin Cronenberg, entitled 'Dream/Awake' shares personal stories of young women TORONTO, May 30, 2012 /CNW/ - In recognition of World MS Day on May 30th, renowned international photographer, Caitlin Cronenberg, has created a first-of-its-kind photo exhibit to showcase the journey young women face when diagnosed with multiple sclerosis (MS). With many women diagnosed in the prime of their lives, three vivacious women from across the country participated in the project and shared their personal stories through a new lens. The national exhibit, entitled DREAM/AWAKE, will be unveiled today in Toronto, featuring Caitlin's visual interpretation of each woman's personal experience with MS. The exhibit takes aim at life after diagnosis, telling a visual tale of the pivotal moment when a young woman learns she has MS and the personal journey that follows. The images demonstrate the feelings of loss - of body, family, opportunity or work - and how each woman has reclaimed her life through treatment and become a figure of inspiration for young women fighting the disease. "The women featured in my exhibit are such an inspiration to … Continue reading →

WESTON, Mass.--(BUSINESS WIRE)-- Today, Biogen Idec (BIIB) will join with the multiple sclerosis (MS) community around the world to celebrate the Fourth Annual World MS Day by hosting diverse educational activities across the globe. Created and led by the Multiple Sclerosis International Federation (MSIF), World MS Day is a global campaign to raise awareness of MS. Every year, the MS movement comes together to provide the public with information about MS and how it affects the lives of more than 2 million people around the world. We have partnered with the global MS community for almost 20 years to raise awareness of this debilitating disease and we feel a deep responsibility to spotlight the needs of the community, said John Richert, M.D., vice president, global medical affairs, Biogen Idec. At Biogen Idec, our philosophy is patients first and we have an unwavering commitment to MS. This years theme for World MS Day focuses on the 1000 Faces of MS, putting people with MS at the heart of the day. The MSIF created 1000 Faces of MS, bringing together stories, messages and support for people living with and affected by MS, providing an opportunity to be a part of the global … Continue reading →

New Delhi, May 29 : All India Institute of Medical Sciences (AIIMS) will be mobilising efforts towards the creation of India specific data at the national level to solve Multiple Sclerosis (MS) and related diseases and provide better lives for those who are suffering from the debilitating disease. Addressing a press conference on the eve of World Multiple Sclerosis Day Head of the Department, Neurology, AIIMS, Prof Madhuri Behari said, "There is a need for better understanding and medications to prevent progression and disability." The AIIMS is keen to set up a National MS Registry for maintenance of epidemiological data of MS patients from across the country for evidence based research, treatment, and education, she said. She added that since 2011, the Department of Neurology has also begun collecting data of MS patients undergoing counselling and treatment at AIIMS on the basis of their demographic profile, medical conditions, quality of life, disability stage and post treatment outcome. Ahead of the World MS day, Additional Professor of Neurology, AIIMS, Dr Rohit Bhatia said the neurology centre at AIIMS today is seeing more patients residing in tier I and tier II cities from across the country. "Therefore efforts are being made to … Continue reading →

28-05-2012 22:56 Follow me on Twiter : @SarahRusty Check out my blog : LUSH Goodies: Ocean Salt Face Scrub Grease Lightning- acne spot treatment Tea Tree Water Toner Jumping Juniper Shampoo Bar (rosemary) Butterball Bath bomb Love Lettuce Fresh Face Mask I hope all of you guys are having an AMAZING day, let me know if you have any video requests, I would love to do any reviews on products or answer questions that you may have! *Disclaimer: All products were bought with my own money and all opinions are my own More here: LUSH Haul May (Budget Friendly Acne/Oily Skin Treatment … Continue reading →

Editor's Choice Main Category: Multiple Sclerosis Article Date: 29 May 2012 - 9:00 PDT Current ratings for: 'World MS Day: Working Towards A Brighter Future' 4.67 (3 votes) In the run-up to WMSD, patient advocacy groups from twenty countries met last weekend in Zurich, Switzerland (May 24th) at a unique Patient Summit which brought together MS societies, activists, MS bloggers and social media experts to learn from each other about how to communicate the challenges of living and working with MS to a wider audience. MS is the leading cause of neurological disability among young and middle-aged adults. Symptoms usually start between the ages of 25 and 31 - a time when adult life is just beginning, when careers are being launched and when plans are being laid for the future. One of the most devastating consequences of MS in this relatively young population is unemployment. A key objective of the Patient Summit was to debate how best to convince employers and policy makers that helping people with MS to remain actively employed is good for both patients and for society. There is growing evidence that helping people with MS continue to work can play a vital role in their … Continue reading →

* No evidence of benefit in long-term clinical trial * Study tested capsules of active cannabis ingredient THC LONDON, May 29 (Reuters) - Cannabis capsules failed to slow the progression of multiple sclerosis in a large British study, dealing a blow to hopes that the drug could provide long-term benefits for patients with the debilitating nerve disease. Despite promising signs in earlier, shorter studies, researchers found patients who took capsules containing tetrahydrocannabinol (THC), a key active ingredient in cannabis, fared no better than those given a placebo. The finding is a disappointment for researchers who thought cannabis might provide a viable therapy in the disease's secondary progressive stage, when patients have few treatment options. Multiple sclerosis (MS) patients were assessed in the trial known as CUPID (cannabinoid use in progressive inflammatory brain disease) on both a disability scale administered by neurologists and another based on their own reporting. "Overall the study found no evidence to support an effect of THC on MS progression in either of the main outcomes," researchers led by John Zajicek of the Peninsula College of Medicine and Dentistry, Plymouth University, said. Results from the study, which was funded by Britain's Medical Research Council, will be presented … Continue reading →